CervoMed Inc. CRVO 深 沪
已收盘 05-08 16:00:00 美东时间
3.95
+0.150
+3.95%
华盛通- 最 高4.153
- 今 开3.84
- 成交量 6.01万股
- 最 低 3.81
- 昨 收 3.80
- 总市值 3657.19万
- 52周最高 13.13
- 市盈率 静 --
- 换手率 0.65%
- 52周最低 3.51
- 委 比 -15.85%
- 总股本 925.87万
- 历史最高 17437.50
- 量 比 1.23
- 振 幅 9.03%
- 历史最低 1.80
- 每 手 1
- 风险率 1.95%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 潜在涨幅15%！15家大行集体上调德州仪器目标价；CSX运输、拉姆研究、金沙集团、马斯可木业、Vertiv Holdings等获多家大行上调目标价
今日重点评级关注：花旗：维持Pegasystems"买入"评级，目标价从70美元升至71美元；巴克莱：维持曼哈顿联合软件"超配"评级，目标价从236美元升至239美元
04-24 12:10
CervoMed Presents Data On Neflamapimod That May Increase Size, Enhance Function Of Basal Forebrain In Participants With Dementia With Lewy Bodies
Today at the 2026 AAN Annual Meeting in Chicago, the first-ever, placebo-controlled magnetic resonance imaging (MRI) analyses providing evidence that neflamapimod may increase the size and enhance the function of the
04-22 19:34
CervoMed To Present Key Aspects Of Neflamapimod Clinical Program At 2026 Lewy Body Dementia Association Annual Meeting, Including Updates On Clinical Findings, Global Regulatory Alignment, And Finalized Phase 3 Trial Design In DLB
Update will include new MRI analyses from the Phase 2b RewinD-LB clinical trial, status of global regulatory discussions, and finalized Phase 3 trial designAdditional data from MRI analyses will also be featured at 2026
04-07 19:39
美股大行评级 | 超多下调！露露乐蒙、Oklo、腾讯音乐、Docusign、BOBS、Bicycle、Academy Sports等遭多家大行下调目标价
今日重点评级关注：花旗：维持Candel Therapeutics"买入"评级，目标价从22美元升至26美元；Chardan Capital：维持CervoMed"买入"评级，目标价从15美元升至21美元
03-19 14:31
Chardan Capital Maintains Buy on CervoMed, Raises Price Target to $21
Chardan Capital analyst Daniil Gataulin maintains CervoMed (NASDAQ:CRVO) with a Buy and raises the price target from $15 to $21.
03-18 20:19
CervoMed Q4 EPS $(0.88) Misses $(0.63) Estimate, Sales $8.726M Beat $966.667K Estimate
CervoMed (NASDAQ:CRVO) reported quarterly losses of $(0.88) per share which missed the analyst consensus estimate of $(0.63) by 40.13 percent. This is a 10 percent decrease over losses of $(0.80) per share from the same
03-17 19:43
CervoMed Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Updates
CervoMed Inc. reported positive Phase 2b RewinD-LB data for its lead drug candidate neflamapimod in dementia with Lewy bodies (DLB) and secured FDA alignment for its planned Phase 3 trial design. The company anticipates multiple catalysts in 2026, including initiating a Phase 3 trial for DLB, reporting Phase 2a results in ischemic stroke recovery and primary progressive aphasia, and launching the EXPERTS-ALS trial in amyotrophic lateral sclerosis...
03-17 11:30
CervoMed Announces Presentations at Upcoming AD/PD™ 2026 Scientific Conference
CervoMed Inc. announced that its drug candidate neflamapimod will be featured in presentations at AD/PD 2026 in Copenhagen, Denmark. The Phase 2b RewinD-LB trial demonstrated significant slowing of clinical progression in dementia with Lewy bodies (DLB) patients without Alzheimer's disease co-pathology. Secondary analyses support the patient selection and dosing regimen for the planned Phase 3 trial, aiming to enrich for DLB patients without AD c...
03-12 11:00
CervoMed to Participate in Upcoming Investor Conferences
CervoMed Inc. announced its participation in two investor conferences in March 2026: the Leerink Global Healthcare Conference on March 11 and the 38th Annual ROTH Conference on March 23, which includes a fireside chat. The company's lead drug candidate, neflamapimod, targeting age-related brain disorders, has completed a Phase 2b trial and plans to initiate a Phase 3 trial later this year. A webcast of the fireside chat will be available on the c...
03-05 12:30
CervoMed Completes Phase 1 Volunteer Trial To Evaluate Pharmacokinetics Of Drug Product Having Only New Stable Crystal Form Of Neflamapimod, Related Updates Regarding Its Planned Phase 3 Trial In Dementia With Lewy Bodies
CervoMed Inc. (CervoMed or the Company) (NASDAQ:CRVO), a clinical-stage biotechnology company developing treatments for age-related brain disorders, today announced that it has successfully completed a Phase 1 healthy
03-04 20:32
